It took 32 months for the research team to meet all the licensing requirements to even conduct the trial. They also commented that the price per dose was literally 50 times more than what it should have cost in a "sane world."

Twelve participants with severe depression signed up to receive high doses of the banned psilocybin. They were given capsules orally and monitored closely.

The medicinal properties of psilocybin were quickly realized. In just one week, all the participants were free of depression and self loathing. After three months, there were no lingering symptoms of depression whatsoever for five of the participants.

The Beckley Foundation's Amanda Feiling participated in the research, and praised the study: "For the first time in many years, people who were at the end of the road with currently available treatments reported decreased anxiety, increased optimism and an ability to enjoy things."